Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC)

被引:0
|
作者
Nakamura, Masaki [1 ,2 ]
Fujisawa, Takeshi [1 ]
Oyoshi, Hidekazu [1 ]
Zhou, Yuzheng [1 ]
Fukushi, Keiko [1 ]
Hirata, Hidenari [1 ]
Tomizawa, Kento [1 ]
Motegi, Atsushi [1 ]
Hojo, Hidehiro [1 ]
Wakabayashi, Masashi [3 ]
Kano, Kazuto [4 ]
Ohno, Risa [4 ]
Nakamura, Azusa [1 ]
Yamaguchi, Masayuki [2 ,5 ]
Zenda, Sadamoto [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Radiat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
[2] Juntendo Univ, Grad Sch Med, Course Adv Clin Res Canc, Tokyo, Japan
[3] Natl Canc Ctr Hosp East, Clin Res Support Off, Biostat Sect, Chiba, Japan
[4] Natl Canc Ctr Hosp East, Dept Radiol Technol, Chiba, Japan
[5] Natl Canc Ctr Hosp East, Dept Radiol, Chiba, Japan
关键词
Breast cancer; Radiotherapy; Adverse event; Hypofractionated; Automated treatment;
D O I
10.1007/s12282-024-01626-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThis single center prospective observational study was conducted to evaluate the acute toxicity of hypo-fractionated radiotherapy for Japanese breast cancer patients after surgery.MethodsThis study recruited patients who were scheduled for moderately hypo-fractionated radiotherapy including supraclavicular lymph node area (Cohort M) or ultra-hypo-fractionated radiotherapy for the conserved breast (Cohort U) as postoperative treatment for breast cancer. Radiotherapy plans were generated using automated planning system. Irradiation of 42.5 Gy/16 fractions (Cohort M) or 26 Gy/5 fractions (Cohort U) was delivered, and boost irradiation of 10 Gy/5 fractions was added as needed. The primary endpoint was the proportion of grade >= 2 acute adverse events within 90 days. The toxicities were evaluated using CTCAE ver 5.0.ResultsBetween January 2023 and December 2023, 123 patients (81 in Cohort M and 42 in Cohort U) were enrolled. All the included patients were Japanese and completed their planned radiotherapy and were also able to be evaluated for acute adverse events. Grade 1/2/3-5 acute adverse events were observed in 67/12/0 for Cohort M and 31/4/0 for Cohort U. The proportion of grade >= 2 acute adverse events within 90 days was 15% (95% confidence interval 8-24%) for Cohort M and 10% (95% confidence interval 3-23%) for Cohort U.ConclusionsThe proportion of acute toxicity of hypo-fractionated radiotherapy for Japanese breast cancer patients after surgery was shown to be acceptable in this study.
引用
收藏
页码:1176 / 1181
页数:6
相关论文
共 50 条
  • [31] Short term toxicity of intraoperative radiotherapy for patients with breast cancer treated at a single center
    Shai, Ayelet
    Zur, Maoz
    Leviov, Michelle
    Bitterman, Arie
    Eitan, Shiloni
    Steiner, Mariana
    CANCER RESEARCH, 2015, 75
  • [32] A COMPARATIVE ANALYSIS OF ACUTE TOXICITIES IN HYPOFRACTIONATED RADIOTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY IN EARLY-STAGE BREAST CANCER AFTER BREAST CONSERVATION SURGERY
    Boggula, Sukrutha
    Gopa, Ashwini
    Mulinti, Suneetha
    Raju, Alluri Krishnam
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2018, 7 (30): : 3348 - 3351
  • [33] Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study
    Habib, Ashraf S.
    Kertai, Miklos D.
    Cooter, Mary
    Greenup, Rachel A.
    Hwang, Shelley
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2019, 44 (02) : 192 - 199
  • [34] THE PILOT STUDY ON ACUTE AND LATE TOXICITY Of HYPOFRACTIONATED RADIOTHERAPY IN LOW-RISK PROSTATE CANCER PATIENTS
    zajusz, A.
    Behrendt, K.
    Nowicka, E.
    Gawkowska-Suwinska, M.
    Plewicki, G.
    Smolska, B.
    Glglok, M.
    Slosarek, K.
    Maciejewski, B.
    RADIOTHERAPY AND ONCOLOGY, 2009, 90 : S19 - S20
  • [35] Toxicity and cosmetic outcome after Intraoperative Radiotherapy with Electrons (IOERT) to the partial breast during breast conserving surgery of breast cancer patients in early stages: First results of a prospective single-center registry trial
    Fastner, G.
    Reitsamer, R.
    Gaisberger, C.
    Stana, M.
    Fussl, C.
    Mattke, M.
    Grambozov, B.
    Zehentmayr, F.
    Sir, A.
    Annon-Eberharter, N.
    Roeder, F.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 59 - 59
  • [36] MICROENCAPSULATED SODIUM BUTYRATE IN THE PREVENTION OF ACUTE RADIOTHERAPY PROCTITIS: SINGLE-CENTER PROSPECTIVE OBSERVATIONAL STUDY
    Bortolus, R.
    Matrone, F.
    Magris, R.
    Maiero, S.
    Arcicasa, M.
    Fornasarig, M.
    Zucchetto, A.
    Guarnieri, G.
    Cannizzaro, R.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S170 - S170
  • [37] Accelerated Hypofractionated Adjuvant Whole Breast Radiotherapy with Concomitant Photon Boost after Conserving Surgery for Early Stage Breast Cancer: A Prospective Evaluation on 463 Patients
    Cante, Domenico
    La Porta, Maria Rosa
    Casanova-Borca, Valeria
    Sciacero, Piera
    Girelli, Giuseppe
    Pasquino, Massimo
    Franco, Pierfrancesco
    Ozzello, Franca
    BREAST JOURNAL, 2011, 17 (06): : 586 - 593
  • [38] Hypofractionated radiotherapy (HR) after breast conserving surgery in breast cancer patients: cosmetic outcome after 2 years of follow up
    Linsenmeier, C.
    Brown, M.
    Glanzmann, C.
    Luetolf, U. M.
    Studer, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 744 - 744
  • [39] An Audit of Hypofractionated Radiotherapy (HFRT) in Breast Cancer Patients Treated at a Tertiary Care Academic Centre: Outcomes and Acute Toxicity
    Lal, P.
    Yadav, R.
    Misra, S.
    Verma, M.
    Das, K. J. Maria
    Kumar, S. K. Senthil
    Kumar, S.
    CLINICAL ONCOLOGY, 2017, 29 (03) : E77 - E77
  • [40] Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results
    Ratosa, Ivica
    Montero, Angel
    Ciervide, Raquel
    Alvarez, Beatriz
    Garcia-Aranda, Mariola
    Valero, Jeannette
    Xin, Chen-Zhao
    Lopez, Mercedes
    Zucca, Daniel
    Hernando, Ovidio
    Sanchez, Emilio
    de la Casa, Miguel Angel
    Alonso, Rosa
    Fernandez-Leton, Pedro
    Rubio, Carmen
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 46